INTERNATIONAL JOURNAL OF PHARMA PROFESSIONAL'S RESEARCH



Role of the Interrelation of Intellectual Property Rights in the Pharmaceutical Industry: A Comprehensive Exploration of Medicinal Accessibility within the Pharmaceutical Industry

Disha Chouhan, Yogesh Dewahe, Shivani Shukla
School of Pharmaceutical Science and Research,
Sardar Patel University, Balaghat (Department of Pharmacy)

Keywords:
Intellectual Property Rights (IPRs), pharmaceutical pricing dynamics, medicinal accessibility, TRIPS compliance, compulsory licensing, pharmaceutical data exclusivity, pharmaceutical industry, innovation incentives, affordable access, global health, pandemic preparedness.

Corresponding Author-
Yogesh Dewahe
Email:
yogeshdewahe7@gmail.com
Sardar Patel University, Balaghat

Volume 15, Issue 2, 2024
Received: 12 April 2024
Accepted: 15 April 2024
Published: 30 April 2024

ABSTRACT: Intellectual property rights (IPR) have been defined as ideas, inventions, and creative expressions based on which there is a public willingness to bestow the status of property. IPR provide certain exclusive rights to the inventors or creators of that property, to enable them to reap commercial benefits from their creative efforts or reputation. There are several types of intellectual property protection like patent, copyright, trademark, etc. Patent is a recognition for an invention, which satisfies the criteria of global novelty, non- obviousness, and industrial application. IPR is prerequisite for better identification, planning, commercialization, rendering, and thereby protection of invention or creativity. Each industry should evolve its own IPR policies, management style, strategies, and so on depending on its area of specialty. Pharmaceutical industry currently has an evolving IPR strategy requiring a better focus and approach in the coming era.

1. Introduction

Intellectual property (IP) pertains to any original creation of the human intellect such as artistic, literary, technical, or scientific creation. Intellectual property rights (IPR) refer to the legal rights given to the inventor or creator to protect his invention or creation for a certain period. These legal rights confer an exclusive

right to the inventor/creator or his assignee to fully utilize his invention/creation for a given period. It is very well settled that IP plays a vital role in the modern economy. It has also been conclusively established that the intellectual labor associated with the innovation should be given due importance so that public good emanates from it. There has been a quantum jump in research and development (R&D) costs with an associated jump in investments required for putting a new technology in the market place. The stakes of the developers of technology have become very high, and hence, the need to protect the knowledge from unlawful use has become expedient, at least for a period, that would ensure recovery of the R&D and other associated costs and adequate profits for continuous investments in R&D. IPR is a strong tool, to protect investments, time, money, effort invested by the inventor/creator of an IP, since it grants the inventor/creator an exclusive right for a certain period of time for use of his invention/creation. Thus IPR, in this way aids the economic development of a country by promoting healthy competition and encouraging industrial development and economic growth. Present review furnishes a brief overview of IPR with special emphasis on pharmaceuticals.

The pharmaceutical sector occupies a significant position in discussions surrounding intellectual property (IP) policy, acting as a focal point for debates on the interplay between IP rights (IPRs), research and development (R&D) incentives, drug pricing, and access to medicines on both national and international levels. The sector's complexity and stringent regulations, including government price controls, insurance schemes, and marketing restrictions, heavily influence pharmaceutical demand. IPRs, particularly patents, impact pricing, access to new medicines, and R&D incentives, posing intricate economic and policy challenges.[1,2]

2. Evolution and Impact of Intellectual Property Rights in India: A Comprehensive Overview

The overview delves into the journey of Intellectual Property Rights (IPRs) in India, spanning from their inception to their current state and future prospects. It outlines the fundamental concepts of IPR, including copyrights, trademarks, and patents, elucidating their role in fostering innovation and creativity while safeguarding the interests of creators and inventors. The historical evolution of Indian IPRs, from pre- independence legislations to post- independence amendments, reflects a dynamic response to domestic needs and international agreements like TRIPS.

The impact of TRIPS compliance on Indian patent regulations is highlighted, emphasizing shifts towardsa product patent system and extending patent protection periods. Despite challenges such as ever greening and workload issues, the patent system aims to balance the interests of patentees with public access through provisions like compulsory licensing. Moreover, the narrative explores the ramifications of these regulations on the pharmaceutical sector, noting initial apprehensions followed by adaptation and growth in indigenous research and development.

Looking ahead, the focus lies on addressing existing. Challenges, fostering industry-academia collaboration, and ensuring equitable access to essential medicines. The future trajectory of the Indian patent system hinges on striking a delicate balance between incentivizing innovation and facilitating affordability, thereby nurturing a conducive environment for sustainable growth and development.[3]

2.1 Understanding the Impact of Intellectual Property Rights on Pharmaceutical Industry in India

IPRs, particularly patents, are pivotal for protecting innovations, incentivizing research and development (R&D), and fostering competitiveness while ensuring public safety. Compliance with international standards, such as the TRIPS Agreement, mandates minimum patent terms and regulates compulsory licensing provisions to prevent monopolies and maintain consumer satisfaction. Compulsory licensing, available after a specified period, aims to prevent market monopolies and ensure consumer access to essential medicines. Processes for drug manufacturing in India are protected for up to seven years from filing or five years from sealing, with ongoing amendments to align with global IPR conventions.

The Patents Act of 1970 sets forth prerequisites for patent protection, emphasizing the safeguarding of manufacturing processes rather than products. IPRs serve as a cornerstone for industrial development, protecting company inventions, fostering healthy competition, and incentivizing innovation crucial for economic growth.

Differences in IPR regimes, from weak to strong, pose economic and ethical considerations. While weak regimes may hinder innovation and allow for imitation, strong ones facilitate innovation funding but risk monopolies and higher drug prices.

Developed countries benefit from robust IPR protection, while developing nations critique it for creating barriers to affordable medicines.

IPRs also combat counterfeit drugs, ensuring consumer safety and penalizing infringers to safeguard public health. In the Indian context, the absence of product patent protection has favored local manufacturers over multinationals, empowering them through reverse engineering methods and gaining market share.

To maintain a competitive edge, pharmaceutical firms must strategically leverage IPRs against generic competition, drive innovation in drug discovery, and ensure strong patent protection for maximum returns

on investment. Effective utilization of IPRs is essential for promoting innovation, ensuring market competitiveness, and sustaining growth in the pharmaceutical sector.

Promoting access to medical innovation. Over the preceding three decades, advancements in medical technologies have wrought profound transformations upon numerous erstwhile untreatable maladies, such as HIV/AIDS, rendering them controllable chronic afflictions. Nonetheless, in light of the evolving global disease landscape, there persists an imperative for the continual development of novel and more efficacious pharmaceuticals. The conundrum confronting policymakers lies in crafting an environment conducive to fostering health innovation while concurrently ensuring widespread accessibility to novel therapeutic interventions tailored to meet unmet global health exigencies.

The conundrums of innovation and accessibility are inexorably interwoven, transcending discrete policy domains, notably those of public health, intellectual property (IP), and international trade. Striking the optimal equilibrium between health imperatives, trade considerations, and IP regimes to nurture innovation while safeguarding broad access to life-preserving technologies represents one of the paramount public policy quandaries of our era.[4,5]

2.2 Management of Intellectual Property in Pharmaceutical Industries

More than any other technological area, drugs and pharmaceuticals match the description of globalization and need to have a strong IP system most closely. Knowing that the cost of

introducing a new drug into the market may cost a company anywhere between $ 300 million to $1000 million along with all the associated risks at the developmental stage, no company will like to risk its IP becoming a public property without adequate returns. Creating, obtaining, protecting, and managing IP must become a corporate activity in the same manner as the raising of resources and funds. The knowledge revolution, which we are sure to witness, will demand a special pedestal for IP and treatment in the overall decision-making process.

Competition in the global pharmaceutical industry is driven by scientific knowledge rather than manufacturing know-how and a company's success will be largely dependent on its R&D efforts. Therefore, investments in R&D in the drug industry are very high as a percentage of total sales; reports suggest that it could be as much as 15% of the sale. One of the key issues in this industry is the management of innovative risks while one strives to gain a competitive advantage over rival organizations. There is high cost attached to the risk of failure in pharmaceutical R&D with the development of potential medicines that are unable to meet the stringent safety standards, being terminated, sometimes after many years of investment. For those medicines that do clear development hurdles, it takes about 8-10 years from the date when the compound was first synthesized. As product patents emerge as the main tools for protecting IP, the drug companies will have to shift their focus of R&D from development of new processes for producing known drugs towards development of a new drug molecule and new chemical entity (NCE). During the 1980s, after a period of successfully treating many diseases of short-term duration, the R&D focus shifted to long duration (chronic) diseases. While looking for the global market, one has to ensure that requirements different regulatory authorities must be satisfied.[6]

3. Nature of Pharmaceutical Industry

The race to unlock the secrets of human genome has produced an explosion of scientific knowledge and spurred the development of new technologies that are altering the economics of drug development. Biopharmaceuticals are likely to enjoy a special place and the ultimate goal will be to have personalized medicines, as everyone will have their own genome mapped and stored in a chip. Doctors will look at the information in the chip(s) and prescribe accordingly. The important IP issue associated would be the protection of such databases of personal information. Biotechnologically developed drugs will find more and more entry into the market. The protection procedure for such drug will be a little different from those conventional drugs, which are not biotechnologically developed. Microbial strains used for developing a drug or vaccine needs to be specified in the patent document. If the strain is already known and reported in the literature usually consulted by scientists, then the situation is simple. However, many new strains are discovered and developed continuously and these are deposited with International depository authorities under the Budapest Treaty. While doing a novelty search, the databases of these depositories should also be consulted. Companies do not usually go for publishing their work, but it is good to make it a practice not to disclose the invention through publications or seminars until a patent application has been filed.[4]

4. IPRs are essential for R&D for future pandemics

The intellectual property (IP) system has played a pivotal role in the unprecedentedly rapid development of multiple vaccines crucial for bringing the current pandemic under control. By providing a sense of certainty, IP rights have incentivized even commercial rivals to collaborate in research efforts, such as sharing

proprietary knowledge resources like compound libraries. Contrary to being a hindrance, IPis fundamental to fostering knowledge creation.

Patent rights necessitate public disclosure, thereby enabling drug developers to identify suitable partners possessing the requisite intellectual assets such as know-how, platforms, compounds, and technical expertise. Without patents, much of this valuable proprietary knowledge would remain concealed as trade secrets, impeding researchers' ability to access critical information.

Additionally, IP laws facilitate collaboration by assuaging concerns about confidentiality, allowing companies to share resources without compromising broader business objectives or losing control of their assets. Waiving IP related to Covid would significantly impede Covid research and development, discouraging private sector investment in vaccines for new variants and hindering preparations for future pandemic preparedness by deterring companies from sharing proprietary knowledge with researchers and partners. Developing countries have historically leveraged the IP system to address health challenges, as evidenced by the Innovate4Health project, which showcases how IP has facilitated the creation of new medicines, vaccines, diagnostics, and delivery modes worldwide. As the Covid-19 crisis abates, there is a pressing need to support developing countries in strengthening their research and development ecosystems, enhancing manufacturing capacity, and fostering economic growth.

The World Trade Organization's Ministerial Decision on the TRIPS Agreement in June 2022 introduced a partial waiver of intellectual property rights, including patent rights for vaccines and the use of protected clinical trial data for vaccine approval.

However, the impact of this waiver has been uneven, with countries like India benefiting from existing infrastructure while many low-income countries,

US and EU law, positioned as 'TRIPS-Plus' levels, extend beyond the requirements of the TRIPS Agreement. Despite industry claims that data exclusivity promotes innovation and safeguards property rights in clinical test data, evidence supporting these assertions is lacking.

In the US, the Drug Competition and Patent Term Restoration Act of 1984 introduced five years of data exclusivity for new drugs, extended to seven years for orphan drugs, with additional protection granted for clinical data on modifications to existing especially in Africa, have not seen significant improvements in vaccination rates. Criticisms have emerged regarding the inadequacy of the WTO Decision, leading to calls for a more comprehensive waiver to address barriers hindering vaccine access in developing countries. Advocacy for a more inclusive solution emphasizes access not only to patents but also to trade secrets and know-how. Questions have been raised about the feasibility of advocating for a comprehensive waiver under the current dynamics of the TRIPS Agreement. Looking beyond the WTO Decision, there is a need for a serious conversation about historical biases, systemic discrimination, and inequality in the application of the TRIPS Agreement. Efforts should focus on increasing manufacturing capacities and ensuring fast and safe delivery of vaccines in low- and middle-income countries.

5. Controversy over Pharmaceutical Data Exclusivity and Its Impact on Access to Medicines in Developing Countries

Since the inception of the WTO TRIPS Agreement in 1994, there has been considerable debate surrounding the influence of

pharmaceutical patent protection on access to medicines, particularly in developing nations. The pharmaceutical industry has vigorously advocated for additional 'regulatory' protection, termed data exclusivity, which restricts the use of clinical trial data for a specified duration, thereby extending the monopoly for the original drug.

Despite the industry's assertions, the ethical underpinnings and arguments in favor of data exclusivity have faced skepticism.

The imposition of data exclusivity by the US and the EU on their trade partners, including developing countries, underscores the pharmaceutical industry's influence. However, provisions for data exclusivity in products and pediatric use. Similarly, the EU mandated a minimum period of data exclusivity of six years in 1987, later extended to ten years, with the possibility of an eleven-year extension for new therapeutic indications offering significant benefits. Orphan drugs in the EU also receive a decade of data exclusivity.

While the TRIPS Agreement does not explicitly require data exclusivity, it mandates the protection of undisclosed data against unfair commercial use, sparking debate over the interpretation of 'unfair commercial use' and its implications for data exclusivity. Bilateral agreements between the US, EU, and other nations have introduced stringent standards for data exclusivity, elevating the threshold for intellectual property rights protection.[7]

The significant influence of business interest groups, particularly multinational pharmaceutical companies, in shaping international intellectual property law cannot be overstated. Lobbying efforts during TRIPS negotiations, such as those by the European Federation of Pharmaceutical Industries and Associations (EFPIA), highlight the industry's concerted push for harmonized data exclusivity periods.

However, the quest for data exclusivity has raised ethical concerns, especially regarding the duplication of clinical trials by generic competitors to avoid accusations of 'free-riding'. This approach is deemed unethical, given the potential risks to volunteers and patients. Furthermore, data exclusivity poses a considerable challenge to affordable access to medicines in developing countries, delaying the availability of generic alternatives and undermining competition

the pharmaceutical industry's pursuit of data exclusivity appears primarily driven by profit motives rather than genuine innovation concerns. Its adverse impact on access to medicines in developing countries and lack of evidence supporting its necessity raise questions about its legitimacy. As such, there is limited justification for embracing data exclusivity, given its considerable risks and negative consequences.

6. The Multifaceted Landscape of Intellectual Property Rights in Pharmaceuticals: Beyond Patents

They predominantly focus on patents, neglecting copyright, trademarks, and sui generis IPRs, and fail to address the efficacy of alternative appropriability mechanisms such as secrecy and speed to market.

Additionally, as highlighted by Lerner (2002) in his examination titled "150 Years of Patent Protection," these comprehensive ranking systems often obscure critical aspects of the patent protection framework, potentially concealing sectoral disparities in its functionality, and do not adequately account for complementary elements of a nation's legal framework. Importantly, these indices primarily reflect the formal de jure status of patent protection, rather than providing an evaluation of

the de facto circumstances confronting holders (or prospective holders) of IPRs at a given moment. Pharmaceuticals serve as a pertinent illustration. While patents reign supreme as the most visible and perhaps paramount form of intellectual property in this sector, other IP mechanisms also wield substantial influence.[8]

In the product market, these encompass copyright for supporting publications and materials, trademark protection for brands, and administrative mechanisms or sui generis provisions conferring proprietary rights in clinical and manufacturing data crucial for regulatory approval. In the realm of research and development (R&D), contract law dictating license agreements, collaborative endeavors, disclosure of proprietary information, along with statutes governing inventor rights versus employer rights and technology transfer by publicly funded institutions, assume critical importance in shaping the dynamics of the "market for technology." Copyright and database protection may also be assuming a growing role as research increasingly relies on bioinformatics and other in silico methodologies to analyze vast databases of genetic, clinical, and bio-physical data (Cockburn (2005)).

The extent of patent coverage in pharmaceuticals has historically exhibited considerable variability. In certain countries, patent protection extends to pharmaceutical products, production processes, treatment protocols and dosage regimens, the use of drugs in treating specific diseases, packaging and delivery mechanisms, and even metabolites of drugs generated in the body during treatment. Conversely, in other jurisdictions, coverage is more circumscribed. Standards concerning obviousness, the level of inventive step, and utility (or industrial application) of the claimed invention have repercussions for the types of drugs likely to be developed for a given market.

As innovation increasingly gravitates towards "large molecules," such as biotechnology, the availability of patent protection for these products or processes for their manufacture assumes heightened significance. Numerous biotechnology products involve therapeutic or diagnostic utilization of proteins or other molecules inherent in nature, albeitin purified, isolated, or modified forms, or genetic modification of living organisms. While excluding such substances (or "naturally occurring processes" that yield them) from patent protection may reflect sound public policy considerations or endeavors to mitigate the costs of exceedingly expensive products, such choices may impact certain countries' access to such "cutting-edge" treatments or diminish commercial incentives to develop these types of drugs for specific diseases or distinct patient populations.[9]

Competitive pressures impel most pharmaceutical companies to seek patent protection for drug candidates very early in the development process, yet the exceptionally protracted development period for atypical product (7-10 years) leaves minimal time to recoup R&D expenditures through an exclusive market position. In some OECD countries, albeit not universally, pharmaceuticals can thus secure patent- term extensions beyond the basic statutory term of 20 years to compensate for delays in the approval process. Additionally, supplementary periods of market exclusivity intended to further policy objectives such as the development of drugs for "orphan" diseases or testing of new drugs in children may also be available.

Exemptions from patent rights exist in numerous jurisdictions to facilitate testing of production processes or preparation of samples to meet regulatory requirements. However, such "Bolar" provisions typically do not extend to stockpiling

of products ahead of patent expiration. For instance, Canada formerly had a specific provision in its Patent Act permitting this, which the WTO deemed to contravene Article 28.1 of the TRIPS Agreement. (Conducting independent clinical trials while a patent is still in force may or may not be covered by the "research exemption" present in the patent law of some countries.) Such rights can significantly influence the pace at which generics penetrate the market and the intensity of generic competition.

In countries with robust generic competition, procedures for challenging/enforcing patents assume critical importance. From the perspective of patent holders, the ability to recoup lost profits from infringers or secure preliminary injunctions against alleged infringers during litigation are pivotal factors influencing the return on R&D investment. Conversely, from the standpoint of prospective entrants (and payers), the ability to invalidate or challenge patents, oppose patent applications, or counter-sue patent holders on the grounds of competition law violations or unfair trading practices assumes equal significance. For both parties, the availability of expeditious, non-discriminatory, transparent, and predictable processes for resolving patent disputes constitutes a material concern, as does "patent quality" – inconsistently or poorly applied standards for patentability are likely to elevate the costs and uncertainty faced by all parties affected by patents.

The strength of patent protection for any given product in a country is further influenced by the interaction between domestic IPRs and trade law. This is especially pertinent in pharmaceuticals, where transportation costs are minimal relative to the product's value, and high-quality manufacturing capacity is geographically concentrated. Provisions governing national exhaustion of IPRs, "reimportation," and parallel trade represent crucial areas, as does the ability of patent holders to leverage customs procedures and trade dispute mechanisms to exclude competitors. A subsidiary trade-related issue pertains to the extent to which a country permits "product by process" protection, namely the right to bar imports of an unpatented or unpatentable drug product (e.g., a naturally occurring protein) if it has been produced abroad using a process patented in the domestic market.[10]

7. Conclusion

The pharmaceutical sector exhibits an exceptional degree of knowledge intensity, with its economic dynamics notably susceptible to Intellectual Property Rights (IPRs). While strides have been taken to elucidate the intricate interplay among IPRs, supplementary regulatory frameworks, and policy measures alongside the industry's global expansion, significant gaps persist in understanding their ramifications on drug pricing, accessibility, research and development (R&D), trade dynamics, and manufacturing. Opportunities abound for the refinement and in-depth scrutiny of extensive data on this intricate and pivotal domain, especially within developing nations and economies undergoing transition.

8. References

1- Intellectual property rights and pharmaceuticals https://www.wipo.int/publications/en/details.jsp

2- Access to medicines through global health diplomacy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025 7564/

3- What is the impact of intellectual property rules on access to medicines? A systematic review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90 13 034/

4- Intellectual Property Protection And The Pharmaceutical Industry https://www.oblon.com/publications/intellectual- property-protection-and-the-pharmaceutical-industry

5- https://blog.petrieflom.law.harvard.edu/2022/11/08/ w hat-happened-to-the-covid-19-vaccine-patent- waiver/

6- A joint declaration on the importance of IPRs to Covid vaccine manufacturing scale-up and future pandemic preparedness https://www.wto.org/english/tratop_e/covid19_e/iprs declaration_e.pdf

7- Raising the Barriers to Access to Medicines in the Developing World – The Relentless Push for Data Exclusivity https://www.ncbi.nlm.nih.gov/pmc/articles/PMC53 47 964/

8- Promoting access to medical innovation https://www.wipo.int/wipo_magazine/en/2013/05/arti cle_0002.html

9- Examining Pharmaceutical Exceptionalism: Intellectual Property, Practical Expediency, and GlobalHealth https://digitalcommons.du.edu/cgi/viewcontent.cgi?article=1223&context=law_facpub

10- Patents, Price Controls, and Access to New Drugs:How Policy Affects Global Market Entry https://papers.ssrn.com/sol3/papers.cfm?